Beta Drugs Limited, part of the Adley Group, is a pharmaceutical formulation manufacturing company specializing in oncology products. Founded in 2005 and based in Himachal Pradesh, India, the company develops, manufactures, and markets drug products globally. It focuses on anti-cancer treatments, offering a range of tablets, capsules, injections, and lyophilized injections. Significant milestones include setting up their first oncology unit in 2008, a cutting-edge manufacturing facility in 2014, and an in-house API plant in 2017. In 2018, Beta Drugs expanded internationally by establishing an oncology plant in Uzbekistan.
The company's product innovations include the launch of GEM-RTU, ADLEAP, ADLANTE, BEXINIB, and the first Indian brands of Dasatinib (BEEDAN) in 2020, and Sunitinib (ADSUNIB) in 2021. Beta Drugs transitioned to a public company in 2017, raising Rs 19.5 Crores through an equity share issue. With a strong focus on oncology, Beta Drugs continues to expand its product offerings and market reach.
